8-K/A: Tivic Health Amends Statera Biopharma License, Modifying Payment Terms and Lien

Tivic Health Systems, Inc. has amended its exclusive license agreement with Statera Biopharma, Inc., revising payment terms to allow for cash or stock and increasing the lien held by Avenue Venture Opportunities Fund, L.P. to up to $5.6 million.

Summary

• Amendment No. 1 to the Current Report on Form 8-K, originally filed June 25, 2025, corrects errors and replaces the Amended and Restated Exclusive License Agreement (A&R License Agreement).
• The A&R License Agreement, effective June 18, 2025, supersedes the Original License Agreement from February 11, 2025, with Statera Biopharma, Inc.
• Key changes include: (i) royalty payments may be made in cash or company securities, at Tivic Health's discretion; (ii) the lien held by Avenue Venture Opportunities Fund, L.P. has increased to up to $5.6 million (the Payoff Amount); and (iii) until the Payoff Amount is paid in full to Avenue, 80% of subsequent payments due to Statera under the agreement (excluding the original license fee and the first Neutropenia milestone payment) will be paid directly to Avenue, with 20% going to Statera.
• Tivic Health previously acquired an exclusive worldwide license to Statera's proprietary Toll-like Receptor 5 (TLR5) agonist program (Entolimod) for the Acute Radiation Syndrome indication and an exclusive option for additional indications (Lymphocyte Exhaustion, Immunosenescence, Neutropenia, Vaccine Adjuvant) and Entolasta.
• Tivic Health exercised its option for the Neutropenia indication on March 28, 2025, and paid the first $500,000 milestone payment in Subsequent Stock Consideration on March 31, 2025.

Sentiment

Score: 5

Explanation: The filing is an amendment to correct errors and clarify terms of an existing material agreement. While it introduces an increased lien amount and diversion of payments, which is a slight negative, it also formalizes the flexibility for Tivic Health to pay in stock, which can be beneficial for cash management. It does not present new, overwhelmingly positive or negative operational or financial results, but rather adjusts the framework of an ongoing strategic partnership.

Positives

• Maintains exclusive worldwide license to proprietary TLR5 agonist program (Entolimod) for Acute Radiation Syndrome.
• Retains exclusive option to expand the license to additional indications (Lymphocyte Exhaustion, Immunosenescence, Neutropenia, Vaccine Adjuvant) and Entolasta.
• Gains flexibility to make royalty and milestone payments in either cash or company securities (stock), which can help preserve cash.
• Has the right, but not the obligation, to acquire all rights, title, and interest in the Licensed Technology (Buyout option).

Negatives

• The lien held by Avenue Venture Opportunities Fund, L.P. has increased to up to $5.6 million, requiring a larger payoff.
• A significant portion (80%) of future payments due to Statera will be diverted directly to Avenue Capital until the $5.6 million lien is fully extinguished.
• Potential for shareholder dilution if Tivic Health opts to make royalty and milestone payments in company stock.
• The agreement requires Stockholder Approval for the conversion of Convertible Preferred Stock into Common Stock, which could introduce uncertainty or delay.

Risks

• Failure to achieve regulatory approvals (IND, BLA) or clinical milestones for Licensed Products, impacting future payments and commercialization.
• Inability to fully extinguish the Avenue Capital lien, potentially affecting future financial flexibility and relationships.
• Shareholder dilution if a substantial amount of payments are made in Subsequent Stock Consideration, potentially impacting stock price.
• Challenges to the validity or enforceability of Licensed Patents by third parties, which could impact exclusivity and commercial viability.
• Potential for infringement of third-party intellectual property rights, despite Licensor's warranties, leading to legal costs or injunctions.
• Dependence on Licensor for certain assistance, cooperation, and transfer of information (e.g., CMC information, Data access).
• Risk of termination if Tivic Health fails to use Commercially Reasonable Efforts to develop and commercialize Licensed Products.

Future Outlook

Tivic Health Systems, Inc. is solely responsible for the development and commercialization of Licensed Products, including non-clinical and clinical studies and CMC information collection, to obtain and maintain Regulatory Approval in the United States and other selected countries. The company is obligated to use Commercially Reasonable Efforts to develop and commercialize Licensed Products consistent with sound business practices. Upon exercising options for additional indications, Tivic Health will be obligated to develop Licensed Products for those indications and file necessary regulatory applications. The company also has the option to acquire full rights to the Licensed Technology through a buyout.

Management Comments

• The Company is filing this Amendment No. 1 to correct errors included in the Original Report regarding the material terms of the A&R License Agreement and to replace the previously filed version with the corrected one.
• The terms and conditions of the A&R License Agreement are substantially similar to those in the Original License Agreement, with material changes including: (i) the Company's discretion to make royalty payments in cash or securities; (ii) an increase in the Avenue Venture Opportunities Fund, L.P. lien to up to $5.6 million; and (iii) the payment of 80% of subsequent payments directly to Avenue on behalf of Statera until the lien is paid in full, excluding the original license fee and the first Neutropenia milestone payment.

Industry Context

This filing highlights a common practice in the biopharmaceutical industry where smaller companies license promising drug candidates from other entities to develop and commercialize them. The focus on TLR5 agonists for indications like Acute Radiation Syndrome, Neutropenia, and Lymphocyte Exhaustion reflects ongoing research into immune system modulation for various medical conditions. The financial structure, including milestone payments, royalties, and the involvement of a lienholder like Avenue Capital, is typical for early to mid-stage drug development agreements, where funding is often tied to specific development achievements and secured against intellectual property.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• The financial terms, including upfront fees, development milestones, and sales royalties, align with general industry practices for exclusive licenses of drug candidates in the biopharmaceutical sector.
• The structure of payments, including the discretion for stock consideration, is a common feature in such agreements, offering flexibility for the licensee.
• The inclusion of a lien and its specific payment mechanism is a particular financial arrangement for this deal, not a universal industry standard for all licensing agreements.

Corporate Governance

Related Party Transactions

• The Amended and Restated Exclusive License Agreement is between Tivic Health Systems, Inc. and Statera Biopharma, Inc.
• Statera Biopharma, Inc.'s affiliate, ImQuest Biosciences, is expected to enter into a Lease Agreement with Tivic Health Systems, Inc. for storage of materials.
• Avenue Venture Opportunities Fund, L.P. holds a lien of up to $5.6 million on the Licensed Technology, and a significant portion of future payments will be directed to Avenue Capital to extinguish this lien.

Stakeholder Impact

• Shareholders: Potential for dilution due to payments made in company stock; long-term value creation dependent on successful development and commercialization of licensed products; clarity on financial obligations and lien resolution.
• Avenue Venture Opportunities Fund, L.P.: Will receive direct payments from Tivic Health Systems, Inc. to extinguish its lien, providing a clear path for repayment.
• Statera Biopharma, Inc.: Will receive 20% of subsequent payments until the Avenue Capital lien is extinguished, and 100% thereafter; benefits from Tivic Health Systems, Inc.'s development efforts for its licensed technology.
• Patients: Potential for new therapeutic options for conditions like Acute Radiation Syndrome, Neutropenia, Lymphocyte Exhaustion, and as a Vaccine Adjuvant, contingent on successful drug development and regulatory approval.

Next Steps

• Tivic Health Systems, Inc. to continue development and commercialization of Licensed Products for Acute Radiation Syndrome and potentially other indications.
• Tivic Health Systems, Inc. to pursue regulatory approvals (IND, BLA) for Licensed Products.
• Tivic Health Systems, Inc. to make milestone and royalty payments as they become due, with 80% of subsequent payments directed to Avenue Capital until the lien is extinguished.
• Statera Biopharma, Inc. to cause Avenue Capital to provide evidence of lien termination upon full payment of the Payoff Amount.
• Tivic Health Systems, Inc. to seek Stockholder Approval for the conversion of Convertible Preferred Stock into Common Stock.

Key Dates

Recommendation

The filing is an amendment to an existing material license agreement, primarily clarifying payment terms and addressing a significant lien. While the increased lien amount and the diversion of future payments to extinguish it are notable financial considerations, the flexibility to pay in stock offers Tivic Health Systems, Inc. operational cash flow benefits. This amendment provides necessary clarity on contractual obligations but does not introduce new fundamental information about the company's operational performance or drug development progress that would warrant a strong buy or sell recommendation. Investors should hold and monitor the company's progress in drug development and financial management.

Keywords

Tivic Health Systems, Statera Biopharma, Exclusive License Agreement, TLR5 Agonist, Entolimod, Entolasta, Acute Radiation Syndrome, Neutropenia, Lymphocyte Exhaustion, Immunosenescence, Vaccine Adjuvant, Biopharmaceutical, Drug Development, SEC Filing, 8-K/A, Royalty Payments, Milestone Payments, Avenue Capital Lien, Stock Consideration, Corporate Governance, Intellectual Property